WINHEALTH PHARMA Re-files HKEX Listing Application with 27 Commercialized Pharmaceutical Assets

NewTimeSpace News: WinHealth International Holding Group Company Limited re-submitted its Main Board listing application to the Hong Kong Stock Exchange on 25 June 2026, with Huatai International appointed as the sole sponsor.

The Group is a comprehensive Chinese pharmaceutical firm specialized in renal disease therapies, with growing end-to-end capabilities in drug R&D, manufacturing and commercialization, dedicated to delivering diversified treatment solutions for nephrology, hematology and other major disease areas. Its product pipeline includes 27 commercialized drugs and one newly approved product, consisting of five assets acquired as part of the Kyowa Kirin China transaction, four exclusively licensed drugs for the Chinese market, and 19 third-party Contract Sales Organization (CSO) products.

The Group is committed to introducing originator and innovative medicines from leading global pharmaceutical corporations into China. It prioritizes patented assets with robust clinical evidence and proven therapeutic efficacy worldwide to deliver high-quality treatment options for Chinese patients. The Group independently manufactures REGPARA® (Cinacalcet Hydrochloride Tablets), while sourcing its active pharmaceutical ingredients (APIs) and raw materials from external suppliers.

The Group generates revenue primarily through pharmaceutical product sales and medical promotion services. All core products have been commercialized in Chinese Mainland, except KORSUVA® (Difelikefalin Injection), which received NMPA approval in April 2026 and is currently undergoing pre-launch preparation.